Get started
Author

Young Nam Lee

Observed name: Young N. Lee
Observed institution: Celltrion (South Korea)
ORCID: 0000-0003-2776-4708
Observed ORCID: 0000-0003-2776-4708
OpenAlex ID: A5084256871
A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
2020 · Tae-Hwan Kim, Shin-Seok Lee, et al. · Clinical Drug Investigation · 21
Retention rate and long-term safety of biosimilar CT-P13 in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics registry
2020 · Hyoun-Ah Kim, Eunyoung Lee, et al. · Clinical and Experimental Rheumatology · 15
PDF
Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
2019 · Hyoun-Ah Kim, Eunyoung Lee, et al. · BioDrugs · 14
PDF
Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease: An individual participant data meta-analysis
2025 · Fraser Cummings, Philip J. Smith, et al. · Journal of Clinical Gastroenterology · 6
Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn’s Disease: A Systematic Literature Review and Network Meta-Analysis
2026 · Stefan Schreiber, Silvio Danese, et al. · Advances in Therapy · 5
PDF
Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate‐to‐Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials
2026 · Jean‐Frédéric Colombel, Silvio Danese, et al. · United European Gastroenterology Journal · 3
Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn’s Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial
2026 · Stefan Schreiber, Bruce E. Sands, et al. · Advances in Therapy · 2
PDF
Endoscopic Response to Subcutaneous Infliximab by Disease Location: A Post Hoc Analysis of the LIBERTY-CD Study
2025 · Bruce E. Sands, Stefan Schreiber, et al. · Clinical Gastroenterology and Hepatology · 2
Su1755 IMPACT OF BODY MASS INDEX ON CLINICAL OUTCOMES AND DRUG LEVELS IN PATIENTS WITH CROHN'S DISEASE RECEIVING MAINTENANCE TREATMENT WITH SUBCUTANEOUS INFLIXIMAB: A POST HOC ANALYSIS OF THE LIBERTY-CD STUDY
2024 · Andres Yarur, Stephen B. Hanauer, et al. · Gastroenterology · 2
Rapid Infusion with CT-P10 in Patients with Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukaemia: Interim Six Month Follow-up from a European Non-Interventional Post-Authorisation Safety Study
2019 · Mark Bishton, Pier Luigi Zinzani, et al. · Blood · 2
Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials
2026 · Marla C Dubinsky, Stefan Schreiber, et al. · Inflammatory Bowel Diseases · 1
Su1848: CHARACTERIZATION OF PATIENTS WHO EXPERIENCE LOSS OF RESPONSE DURING MAINTENANCE TREATMENT WITH SUBCUTANEOUS INFLIXIMAB (IFX SC): A POST HOC ANALYSIS OF THE 2-YEAR PHASE 3 LIBERTY-CD AND LIBERTY-UC TRIALS
2025 · Marla Dubinsky, Bruce E. Sands, et al. · Gastroenterology · 1
Su1765 IMPACT OF IMMUNOGENICITY ON CLINICAL OUTCOMES IN PATIENTS WITH CROHN'S DISEASE RECEIVING MAINTENANCE TREATMENT WITH SUBCUTANEOUS INFLIXIMAB: A POST HOC ANALYSIS OF THE LIBERTY-CD STUDY
2024 · Jean Frederic Colombel, Silvio Danese, et al. · Gastroenterology · 1
Network Meta-analysis to Evaluate the Comparative Efficacy of Biologics for Maintenance Treatment of Adult Patients With Crohn’s Disease
2024 · Stefan Schreiber, Silvio Danese, et al. · Inflammatory Bowel Diseases · 1
PDF
Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe
2022 · Mark J. Bishton, Gilles Salles, et al. · eJHaem · 1
PDF
The safety and clinical effectiveness of rapid infusion with CT‐P10 in patients with non‐Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non‐interventional post‐authorization safety study in Europe
2022 · Mark Bishton, Scott Marshall, et al. · Hematological Oncology · 1
444 Recapturing Disease Control With Subcutaneous Infliximab After a Drug Holiday Following Intravenous Infliximab Induction: a Post Hoc Analysis of Liberty-cd and -uc Studies
2026 · Marla C. Dubinsky, Bruce E. Sands, et al. · Gastroenterology
444 Recapturing Disease Control With Subcutaneous Infliximab After a Drug Holiday Following Intravenous Infliximab Induction: a Post Hoc Analysis of Liberty-cd and -uc Studies
2026 · Marla C. Dubinsky, Bruce E. Sands, et al. · Gastrointestinal Endoscopy
Pharmacokinetics and efficacy of subcutaneous infliximab 120 mg every 2 weeks: a post hoc comparison with intravenous dosing in a phase 1 study in patients with inflammatory bowel disease.
2026 · Stefan Schreiber, Byong Duk Ye, et al. · PubMed Central
PDF
A retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab
2025 · Xenofon Baraliakos, Ye Eun Lee, et al. · BMC Rheumatology
PDF
Su1842: IMPACT OF IMMUNOGENICITY ON 2-YEAR CLINICAL OUTCOMES IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE TREATED WITH SUBCUTANEOUS INFLIXIMAB: A POST HOC ANALYSIS OF THE PHASE 3 LIBERTY-CD STUDY
2025 · Bruce E. Sands, Jean Frederic Colombel, et al. · Gastroenterology
Su1847: TIME TO CLINICAL RECAPTURE AFTER DOSE ESCALATION OF SUBCUTANEOUS INFLIXIMAB FOLLOWING LOSS OF RESPONSE: A POST HOC ANALYSIS OF THE 2-YEAR PHASE 3 LIBERTY-CD & LIBERTY-UC TRIALS
2025 · Marla Dubinsky, Stefan Schreiber, et al. · Gastroenterology
Su1870: EFFICACY OF SUBCUTANEOUS INFLIXIMAB MAINTENANCE THERAPY ACCORDING TO DISEASE LOCATION IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: A POST HOC ANALYSIS OF THE PHASE 3 LIBERTY-CD STUDY
2025 · Stefan Schreiber, Jean Frederic Colombel, et al. · Gastroenterology
Su1866: ENDOSCOPIC AND HISTOLOGIC OUTCOMES IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS TREATED WITH SUBCUTANEOUS INFLIXIMAB: A POST HOC ANALYSIS OF THE PHASE 3 LIBERTY-UC STUDY
2025 · Jean Frederic Colombel, Stephen B. Hanauer, et al. · Gastroenterology
Impact of Immunogenicity on Clinical Outcomes in Patients With Ulcerative Colitis Receiving Maintenance Treatment With Subcutaneous Infliximab: a Post Hoc Analysis of the Liberty-uc Study
2025 · Jean-Frederic Colombel, Silvio Danese, et al. · Gastroenterology
PDF
Works count: 34
Citation count: 78
H-index: 5
I10-index: 3
Year
Topic
Type